Your browser is no longer supported. Please, upgrade your browser.
OTLK Outlook Therapeutics, Inc. daily Stock Chart
OTLK [NASD]
Outlook Therapeutics, Inc.
Index- P/E- EPS (ttm)-5.48 Insider Own0.20% Shs Outstand23.71M Perf Week16.83%
Market Cap55.96M Forward P/E- EPS next Y-1.59 Insider Trans- Shs Float12.23M Perf Month14.56%
Income-42.90M PEG- EPS next Q-0.36 Inst Own7.00% Short Float11.25% Perf Quarter52.26%
Sales3.30M P/S16.96 EPS this Y27.00% Inst Trans412.73% Short Ratio0.26 Perf Half Y-57.02%
Book/sh-2.44 P/B- EPS next Y-5.70% ROA-186.10% Target Price7.50 Perf Year-67.22%
Cash/sh0.01 P/C279.78 EPS next 5Y- ROE184.20% 52W Range0.85 - 10.96 Perf YTD-41.00%
Dividend- P/FCF- EPS past 5Y- ROI778.50% 52W High-78.47% Beta-
Dividend %- Quick Ratio0.10 Sales past 5Y- Gross Margin- 52W Low177.65% ATR0.21
Employees56 Current Ratio0.10 Sales Q/Q-25.00% Oper. Margin- RSI (14)55.98 Volatility14.32% 7.92%
OptionableNo Debt/Eq- EPS Q/Q63.20% Profit Margin- Rel Volume0.08 Prev Close2.46
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume5.38M Price2.36
Recom1.50 SMA208.78% SMA5010.72% SMA200-51.94% Volume446,052 Change-4.07%
May-16-19Initiated Oppenheimer Outperform $12
Apr-22-19Initiated Ascendiant Capital Markets Buy
Jul-19-19 12:39PM  A Look At Benzinga Pro's Most-Searched Tickers For July 19, 2019 Benzinga -6.84%
Jul-18-19 12:05PM  A Look At Benzinga Pro's Most-Searched Tickers For July 18, 2019 Benzinga +34.87%
Jul-16-19 08:00AM  Outlook Therapeutics Doses First Patient in the Second Phase 3 Clinical Trial for ONS-5010 in Wet AMD GlobeNewswire
Jun-03-19 08:57AM  Hottest Wall Street Stories: What's Up, What's Down Zacks +7.50%
08:00AM  Outlook Therapeutics Signs Manufacturing Supply Agreement with FUJIFILM Diosynth Biotechnologies as Part of Commercialization Strategy for ONS-5010 GlobeNewswire
May-24-19 12:50PM  A Look At Benzinga Pro's Most-Searched Tickers For May 24 Benzinga +42.35%
May-20-19 09:02AM  Outlook Therapeutics stock rockets on heavy volume again, set to triple in 3 days MarketWatch +42.86%
May-17-19 03:17PM  Outlook Therapeutics Rallies 150% In 2 Days: What You Need To Know Benzinga +37.25%
09:47AM  Outlook Therapeutics' stock rockets on heavy volume again, has more than doubled in 2 days MarketWatch
May-16-19 09:48AM  Outlook Therapeutics started at outperform with $12 stock price target at Oppenheimer MarketWatch +68.06%
May-15-19 08:00AM  Outlook Therapeutics Provides Business Update and Reports Second Quarter Financial Results for Fiscal 2019 GlobeNewswire -11.62%
Apr-26-19 08:00AM  Outlook Therapeutics Announces Addition of Jennifer M. Kissner, Ph.D. as Senior Vice President, Clinical Development GlobeNewswire +6.82%
Apr-10-19 09:00AM  Outlook Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants GlobeNewswire -45.08%
Apr-01-19 08:00AM  Outlook Therapeutics Announces FDA Acceptance of IND for ONS-5010 GlobeNewswire
Mar-15-19 09:00AM  Outlook Therapeutics Announces Reverse Stock Split GlobeNewswire
Mar-05-19 08:00AM  Outlook Therapeutics Regains Compliance With All Nasdaq Listing Requirements GlobeNewswire -6.49%
Mar-01-19 08:00AM  Outlook Therapeutics Submits IND Application for ONS-5010 to the FDA GlobeNewswire
Feb-14-19 08:00AM  Outlook Therapeutics Provides Business Update and Reports First Quarter Financial Results for Fiscal 2019 GlobeNewswire +24.27%
Feb-13-19 11:45AM  Healthcare Investment Opportunities You Can't Miss ACCESSWIRE
Feb-01-19 09:15AM  Outlook Therapeutics Closes Final Tranche of $20 Million Private Placement GlobeNewswire
Jan-22-19 09:00AM  Outlook Therapeutics Announces Exercise Price Reduction and Term Extension of Series A Warrants GlobeNewswire
Jan-02-19 09:15AM  Outlook Therapeutics Closes Third Tranche of $20 Million Private Placement GlobeNewswire +10.00%
Dec-18-18 09:00AM  Outlook Therapeutics Provides Business Update and Reports Financial Results for Fiscal Year 2018 GlobeNewswire +14.29%
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases. The company has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in December 2018. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.